Showing results (81-90 of 129) with videos related to

Sort By:
Pageof 13
Biotechnology Progress|August 5, 2020
Sensitivity of a PER.C6® cell line to bis(2,4-di-tert-butylphenyl)phosphate and evaluation of a new, biocompatible single-use filmJoshua R Jachuck, Soumya Mohanan Krishnathu, Jeffrey E Landau, et al.
Advances in Shock Research|January 1, 1979
Oxygen consumption in canine skeletal muscle following massive saline infusionS E Landau, S R Powers, R S Alexander, et al.
Journal of Child Neurology|May 3, 2001
Cognition, attention, and behavior in Prader-Willi syndromeV Gross-Tsur, Y E Landau, F Benarroch, et al.
American Journal of Therapeutics|July 29, 1999
Prostaglandin E1 : electrophysiological safety in patients with congestive heart failure and peripheral arterial occlusive disease. The Alprostadil InvestigatorsJ C Somberg, V Yelamanchi, J Molnar, et al.
British Journal of Biomedical Science|October 17, 2003
Impaired nitric oxide production, brachial artery reactivity and fish oil in offspring of ischaemic heart disease patientsC Yosefy, V Khalamizer, J R Viskoper, et al.
The American Journal of Occupational Therapy : Official Publication of the American Occupational Therapy Association|May 7, 2014
Effectiveness of Cognitive-Functional (Cog-Fun) occupational therapy intervention for young children with attention deficit hyperactivity disorder: a controlled studyAdina Maeir, Orit Fisher, Ruthie Traub Bar-Ilan, et al.
Developmental Medicine and Child Neurology|October 19, 2006
The impact of sex and subtypes on cognitive and psychosocial aspects of ADHDVarda Gross-Tsur, Gil Goldzweig, Yael E Landau, et al.
Muscle & Nerve|February 16, 2012
Serum creatine kinase after exercise: drawing the line between physiological response and exertional rhabdomyolysisKimbra Kenney, Mark E Landau, Rodney S Gonzalez, et al.
Acta Neurologica Belgica|February 15, 2023
Clinical score for early diagnosis and treatment of stroke-like episodes in MELAS syndromeJonathan Naftali, Maor Mermelstein, Yuval E Landau, et al.
European Journal of Heart Failure|August 21, 2001
Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failureG Cotter, W Kiowski, E Kaluski, et al.
Pageof 13